- Home
- GMAB vs EWBC Comparison
GMAB vs EWBC Comparison
Compare GMAB & EWBC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GMAB
- EWBC
- Stock Information
- Founded
- GMAB 1999
- EWBC 1998
- Country
- GMAB Denmark
- EWBC United States
- Employees
- GMAB N/A
- EWBC N/A
- Industry
- GMAB Biotechnology: Pharmaceutical Preparations
- EWBC Major Banks
- Sector
- GMAB Health Care
- EWBC Finance
- Exchange
- GMAB Nasdaq
- EWBC Nasdaq
- Market Cap
- GMAB 15.0B
- EWBC 14.9B
- IPO Year
- GMAB N/A
- EWBC 1999
- Fundamental
- Price
- GMAB $20.45
- EWBC $105.50
- Analyst Decision
- GMAB Buy
- EWBC Strong Buy
- Analyst Count
- GMAB 8
- EWBC 13
- Target Price
- GMAB $43.00
- EWBC $99.46
- AVG Volume (30 Days)
- GMAB 1.5M
- EWBC 904.5K
- Earning Date
- GMAB 11-06-2024
- EWBC 10-22-2024
- Dividend Yield
- GMAB N/A
- EWBC 2.09%
- EPS Growth
- GMAB 14.35
- EWBC N/A
- EPS
- GMAB 10.80
- EWBC 7.92
- Revenue
- GMAB $2,967,926,227.00
- EWBC $2,413,809,000.00
- Revenue This Year
- GMAB $30.31
- EWBC N/A
- Revenue Next Year
- GMAB $16.49
- EWBC $4.02
- P/E Ratio
- GMAB $18.39
- EWBC $13.33
- Revenue Growth
- GMAB 17.75
- EWBC 3.60
- 52 Week Low
- GMAB $20.37
- EWBC $60.34
- 52 Week High
- GMAB $32.88
- EWBC $107.68
- Technical
- Relative Strength Index (RSI)
- GMAB 25.28
- EWBC 65.36
- Support Level
- GMAB $20.50
- EWBC $101.93
- Resistance Level
- GMAB $23.47
- EWBC $107.68
- Average True Range (ATR)
- GMAB 0.45
- EWBC 2.74
- MACD
- GMAB -0.18
- EWBC -0.25
- Stochastic Oscillator
- GMAB 2.74
- EWBC 83.37
About GMAB Genmab A/S ADS
Genmab AS is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.
About EWBC East West Bancorp Inc.
East West Bancorp Inc is the holding company for East West Bank, a full-service commercial bank with cross-border operations concentrated in the United States and China. East-West Bank is one of a few U.S. based banks with a full banking license in China. The bank's cost strategy has increasingly focused on expanding its deposit base away from time deposits to commercial deposits. The bank has also taken part in entertainment partnerships between participants in China and Hollywood. Most of these efforts include financing the production and distribution of film and television projects. The bank leverages its cultural and regulatory knowledge in the U.S. and China to assist its customers in entering new markets. Most of its earning assets are in loans held for investment.